---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-026568"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T12:42:54.133637+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ardelyx Q2 2023: IBSRELA rev $18.3M (+61% QoQ), net loss $17.1M, FY23 guidance $72-77M

## Summary
- IBSRELA net sales $18.3M in Q2 2023, up 61% QoQ from $11.4M in Q1.
- Total revenues $22.3M (incl $4.0M licensing); net loss $17.1M ($0.08/sh) narrowed from $26.9M loss in Q2 2022.
- FY2023 IBSRELA net sales guided to $72-77M; management sees $500M+ peak sales potential.
- XPHOZAH NDA under FDA review (PDUFA Oct 17, 2023); launch prep underway for Q4 2023 pending approval.
- Cash $127.6M at June 30, 2023; raised $11.6M via ATM in Q2.

## SEC filing metadata
- accession: 0001628280-23-026568
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828023026568/0001628280-23-026568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828023026568/ardx-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-026568
- JSON: https://secwatch.observer/filing/0001628280-23-026568.json
- Plain text: https://secwatch.observer/filing/0001628280-23-026568.txt

## Key facts
- Earnings Releases
  ARDELYX, INC. reported second quarter ended June 30, 2023 results: revenue $22.3 million. Guidance raised.
  - Period: second quarter ended June 30, 2023
  - Revenue: $22.3 million
  - Guidance: raised
  - Result: reported results
  source text: for IBSRELA were $18.3 million during the quarter ended June 30, 2023, compared to $1.6 million for the quarter ended June 30, 2022. Total revenues for the second quarter were $22.3 million, which included $4.0 million of product supply and licensing related revenue compared to $1.0 million in product supply and licensing related revenue in the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1437402/000162828023026568/0001628280-23-026568-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.